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Do health techNology ageNcIes accept methoDs for DealINg wIth 
treatmeNt swItchINg?
Maervoet J.1, Skaltsa K.2, Ivanescu C.1, Van Engen A.1
1Quintiles Consulting, Hoofddorp, The Netherlands, 2Quintiles Consulting, Barcelona, Spain
Objectives: Upon disease progression or early termination of a trial, cancer 
patients in the control arm of clinical studies commonly switch to the experimental 
drug or receive other post-study treatments. The objective of this study was to assess 
the willingness of HTA agencies to accept the statistical methods that are available 
to adjust overall survival (OS) estimates for resulting bias. MethOds: PubMed and 
the ADIS R&D Insights database were searched to identify pivotal trials involv-
ing treatment switching. Related HTA appraisals, published between January 2011 
and February 2014, were then selected from the HTA agencies websites for further 
analysis. Reports from 10 agencies were considered for review. Results: Sixteen 
pivotal trials and 45 related HTA appraisals were selected for in-depth analysis. 
It was widely acknowledged by all HTA agencies that treatment switching could 
confound the OS estimates when an inferior drug is used as a comparator. Our 
analysis suggests that statistical adjustment methods are discussed more often 
and more thoroughly by agencies that base their decisions on cost-effectiveness 
outcomes. On one end, NICE accepts and reviews the selection and implementation 
of such methods in detail, and has recently developed its own guidelines on the 
appropriate handling of treatment switching. Various examples have been identi-
fied and accepted in SMC and PBAC submissions. TLV, ZiNL, pCODR and INESSS 
have accepted statistical adjustments in at least one case. No evidence of such 
adjustments was identified in the selected HAS reports. On the other end, recent 
case examples among IQWiG submissions suggest that they do not accept the use 
of these methods. cOnclusiOns: The rationale to adjust for treatment switching 
and the methods used need to be justified towards agencies accepting the correc-
tion techniques. Other payers will rather want to base their decision on results of 
the last “unbiased” dataset.
research oN methoDs - prefereNce stuDIes
pr1
survIval or mortalIty: framINg of the rIsk attrIbute IN a DIscrete 
choIce experImeNt
Veldwijk J.1, Essers B.A.B.2, Dirksen C.D.3, Smit H.A.4, Lambooij M.S.1, de Wit G.A.1
1National Institute for Public Health and the Environment, Bilthoven, The Netherlands, 2Clinical 
and Medical Technology Assessment, Maastricht University Medical Centre; CAPHRI, Maastricht 
University, Maastricht, The Netherlands, 3Department of Clinical Epidemiology and Medical 
Technology Assessment, Maastricht University Medical Centre, Maastricht, The Netherlands, 
4University Medical Center Utrecht, Utrecht, The Netherlands
Objectives: To empirically test whether and how framing of a risk attribute 
in a Discrete Choice Experiment (DCE) affects study results with respect to the 
relative importance of the attributes, trading behavior and potential uptake 
rates. MethOds: By means of ongoing data collection, two versions of a DCE- 
questionnaire containing nine D-efficiently designed choice tasks were distrib-
uted among a representative sample of the Dutch population aged 55-65years. The 
DCE consisted of four attributes related to the decision whether to participate in 
genetic screening for colorectal cancer (CRC). Three fixed attributes were; risk of 
being genetically predisposed, risk of developing CRC, and frequency of follow-up 
colonoscopies. The included risk attribute was framed positively as survival rate 
and negatively as mortality rate. Mixed logit models were conducted to estimate the 
relative importance of the attributes. Dominant decision behavior was determined 
and potential uptake rates were calculated. Results: Overall, risk attribute fram-
ing significantly interacted with most of the attribute level estimates. Based on 
the positive frame, the frequency of follow-up colonoscopies was most important 
followed by survival rate, while based on the negative fame, mortality rate was 
most important. Twice as many respondents dominated on the survival attribute 
compared to the mortality attribute. Potential uptake rates were calculated for mul-
tiple hypothetical scenarios, in all cases they were lower based on the data of the 
negative frame. cOnclusiOns: The use of a positive frame leads to significantly 
increased frequency of dominant choices. Negative framing of the risk attribute 
resulted in a different relative importance of the attributes and a lower willingness 
to participate in genetic screening for CRC compared to positive framing. These 
results call for greater attention and more research with regard to the impact of 
framing of risk attributes in DCEs aiming to elicit preferences within the health 
care or public health context.
pr2
mappINg from sf-6D to eQ-5D: chaNges IN estImates baseD oN the 
choIce of algorIthm
Hatswell A.J.1, Ito T.2, Ganguly R.3, Nassens D.4, Almond C.1
1BresMed, Sheffield, UK, 2Janssen-Cilag Ltd, High Wycombe, UK, 3Janssen R&D, LLC, Spring 
House, PA, USA, 4Janssen BVBA, Beerse, Belgium
Objectives: Where data collected using a preferred utility instrument are not avail-
able, mappings may be available to link either disease specific or generic quality 
of life instruments to the preferred measure. The objective of this study was to 
investigate the similarity of a widely used older mapping from SF-36 to EQ-5D and 
a more recently published mapping linking the same two instruments. MethOds: 
Patient level SF-36 data from the PSUMMIT trials of ustekinumab versus placebo in 
psoriatic arthritis (PsA) were used to generate EQ-5D utilities based upon the older 
algorithm (Gray) and the newer algorithm (Rowen). A regression linking disease 
specific instruments to the resulting EQ-5D utilities, used in a published economic 
evaluation of anti-TNFα treatments for PsA, was also replicated to investigate the 
difference the choice of mapping would make if the results were used in economic 
analysis. Results: The mapping algorithms showed similar mean values (Gray 
= 0.572, Rowen = 0.568) and a large degree of agreement in estimates (R2 = 0.95). 
Objectives: New health technologies are required to demonstrate clinical- and 
cost-effectiveness before being recommended by NICE for use in the National 
Health Service. A large proportion of submissions are rejected, at least in part, 
due to poor trial design or flaws in the presented clinical data. Published NICE 
guidance includes a comprehensive critique of submitted clinical evidence. 
Therefore, the flaws in clinical data leading to rejection by NICE were examined, 
as a means of providing guidance for future submissions. MethOds: All single 
technology appraisals from January 2006 to May 2014 from NICE were included 
in the analysis. Multiple technology appraisals, resubmissions, vaccination pro-
grammes, and requests for advice were excluded. The recommendation and rea-
soning behind each decision were assessed, focusing on the critique of the clinical 
evidence. Results: 121 NICE submissions met the inclusion criteria, of which 28 
(19.8%) were rejected. Notable flaws in the presented clinical data were reported 
in 22 (78.6%) of the submissions. Major drivers of rejection due to clinical flaws 
included: uncertainty in the clinical evidence (32.1%), statistical flaws in trial 
design (28.6%), flaws in the choice of comparator (17.9%), and a perceived lack 
of transparency in trial design (14.3%). These factors contributed to a perceived 
failure to demonstrate clinical superiority over the comparator in 42.9% of the 
rejected submissions. cOnclusiOns: A failure to convincingly demonstrate clini-
cal superiority is a major driver in the rejection of submissions to NICE, often 
due to clinical trial design weaknesses or uncertainty surrounding the data pre-
sented. Manufacturers should not underestimate the need for effective planning 
and review of trial design early in the clinical development process, in order to 
avoid rejection by HTA agencies in later development stages.
NI2
preDIctINg the Impact of value-baseD assessmeNt oN future  
NIce appraIsals
Beale R.C., Maruszczak M., Kusel J.
Costello Medical Consulting Ltd., Cambridge, UK
Objectives: Value-based assessment will be introduced into National Institute for 
Health and Care Excellence (NICE) appraisals where the willingness-to-pay above 
£20,000 will depend upon the wider societal impact (absolute shortfall of quality-
adjusted life years [QALYs]) and burden of illness (proportional QALY shortfall). The 
objective of this research was to re-evaluate past appraisals and determine whether 
there was a relationship between the absolute and proportional QALY shortfalls and 
the NICE decision. MethOds: Final incremental cost-effectiveness ratios (ICERs) 
were identified from NICE single technology appraisals published between January 
2013 and May 2014. The age that treatment commenced was taken from manu-
facturer submissions and combined with the average life expectancy in the UK to 
calculate the discounted QALYs accrued by a healthy person (X). Discounted QALYs 
accrued by current treatment were extracted from manufacturer submissions (Y). 
Consequently, absolute (X-Y) and proportional (absolute/X) QALY shortfalls were 
calculated for each condition. Logistic regression (LR) was performed on the data. 
Appraisals were excluded if the manufacturer submission was missing. Results: 
Of the appraisals assessed, 23 appraisals met the selection criteria; 13 were recom-
mended and 10 not recommended by NICE. The LR confirmed that the probability 
of an intervention being recommended was reduced significantly if the ICER was 
> £30,000 (p< 0.05). Taking into account the ICER, LR analysis demonstrated that 
neither the proportional nor absolute QALY shortfall had a significant effect on 
recommendation by NICE (p> 0.05). cOnclusiOns: These results suggest that in 
recent appraisals, proportional and absolute QALY shortfalls have had no significant 
effect on the NICE committee’s decisions, and that the introduction of value-based 
assessment may therefore cause a substantial change in the future outcomes of HTA 
processes. It is recognised that further appraisals before 2013 should be evaluated 
to confirm these results, as the sample size was small.
NI3
NIce’s proposeD value-baseD assessmeNt of health techNologIes: 
coNcerNs of INcoNsIsteNt coNsIDeratIoN of socIal values
Paulden M.1, O’Mahony J.F.2, Culyer A.J.3, McCabe C.1
1University of Alberta, Edmonton, AB, Canada, 2Trinity College Dublin, Dublin, Ireland, 
3University of Toronto, Toronto, ON, Canada
bAckgROund: The UK’s National Institute for Health and Care Excellence (NICE) 
recently proposed amendments to its health technology appraisal methods. Previous 
amendments in 2009 and 2011 placed a greater value on the health of patients at the 
“end of life” and in cases where “treatment effects are both substantial in restoring 
health and sustained over a very long period”. The recent proposals repeal “end of 
life” considerations but add consideration of the “proportional” and “absolute” QALY 
loss from illness. NICE’s cost-effectiveness threshold may increase from £20,000 to 
£50,000 per QALY based upon these and four other considerations: “certainty of 
the ICER”; if health related quality of life is “inadequately captured”; the “innova-
tive nature” of the technology; and “non-health objectives of the NHS”. AnAlysis: 
We demonstrate that NICE’s previous amendments are flawed for two reasons: 
they contain logical inconsistencies which can result in different values being 
placed on health gains for identical patients, and they do not apply value weights 
to patients bearing the opportunity cost of NICE’s recommendations. The newly 
proposed amendments also suffer from a third flaw that the suggested weightings 
are poorly justified. The second of the three flaws is particularly significant, as the 
failure to apply special considerations to displaced services may result in NICE’s 
cost-effectiveness threshold being too high to adequately represent opportunity 
cost. Furthermore, the baseline threshold of £20,000 per QALY is greater than current 
estimates of the opportunity cost. Overall, these flaws likely lead to several undesir-
able consequences including age discrimination, a systematic bias in favour of new 
interventions over existing services, and the displacement of effective interventions 
by less effective interventions. cOnclusiOn: NICE’s proposed threshold range is 
too high, for empirical and methodological reasons. NICE’s proposals will harm 
the health of unidentified patients, whilst privileging the identified beneficiaries 
of new health technologies.
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during face-to-face interviews with a minimum representative sample (n= 100) of 
the general population, per-country, in Australia, Canada, France, Japan, Spain and 
the UK. Visual Analog Scale (VAS) scores were obtained to validate TTO scores. TTO 
scores were converted into utility values. Results: The highest mean TTO utility 
scores (range 0.66-0.82) were observed for the anchor HS (minimal disease activity) 
across all countries. All flare HS were associated with a disutility compared with the 
anchor HS: mild flare HS (0.55-0.71), moderate flare HS (0.38-0.53), severe renal flare 
HS (0.33-0.45), severe Central Nervous System (CNS) flare HS (0.30-0.45) and severe 
generalised flare HS (0.19-0.33). Significant differences were reported between the 
anchor state and each flare state across all countries (p< 0.05). Mean VAS scores 
followed the same trend. The severe generalised flare HS received the lowest mean 
TTO utility score across all six countries suggesting that the perceived day-to-day 
impact of a severe generalised flare was greater than a severe CNS or severe renal 
flare. cOnclusiOns: These results show that a decrease in utility, representing a 
detrimental impact on HRQoL, was observed with increasing severity of flare. These 
results could be applied in cost-utility analyses for interventions for SLE.
Ql2
the Impact of DIscrImINatIoN, vIctImIzatIoN aND socIal staNDINg oN 
health-relateD QualIty of lIfe
Samnaliev M.
Boston Childrens Hospital, Boston, MA, USA
Objectives: To examine the link between discrimination, victimization and social 
standing on health-related quality of life (HRQL). This information is currently not 
known, but is crucial as it can aid decision makers in the design of cost-effective pol-
icies to reduce such victimization among specific minority populations. MethOds: 
We used data from 6,194 females and males from a prospective cohort of youth 
that has been tracked for over 15 years. We specifically examined the impact of 
discrimination, victimization and social standing of sexual orientation minorities 
on their HRQL (using EQ-5D-5L). In 2013, participants reported sexual orientation 
(Completely Heterosexual [CH], Mostly Heterosexual [MH], Bisexual [B], and Lesbian/
Gay [LG])). Participants previously reported past-year bullying victimization and 
discrimination (range: 1 [never] to 5 [several times/week]) and self-perceived social 
standing (range: 1 [top] to 10 [bottom]) in adolescence. Longitudinal, multivariable 
linear regression models were used to assess the effect of bullying and social stand-
ing in adolescence on sexual orientation HRQL score disparities in young adult-
hood, controlling for gender and age. Results: Compared to CHs, sexual minorities 
reported more bullying and lower social standing in adolescence and lower HRQL 
in young adulthood: MH HRQL score= 0.880; B 0.845; LG 0.870 vs. CH 0.916 (all differ-
ences had p-values< 0.05). When discrimination, victimization and social standing 
were added to the multivariable models, orientation-group effect estimates were 
attenuated ~10%, suggesting adolescent bullying and lower social standing partly 
explained HRQL disparities in young adulthood. cOnclusiOns: Our findings are 
a proof of concept that victimization is not only a social justice issue but imposes 
an economic burden on society, as evidenced by its impact on HRQL.Our findings 
can also be used in cost-effectiveness analyses of interventions to reduce stigma 
against sexual orientation minorities.
Ql3
QualIty of lIfe DecremeNts after stroke
Dewilde S.1, Thijs V.2, Annemans L.3, Peeters A.4, Belgian Stroke Council N.P.5
1SHE, Brussels, Belgium, 2KULeuven, Leuven, Belgium, 3Ghent University & Brussels University, 
Ghent, Belgium, 4Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, 5Virga Jesseziekenhuis, 
Hasselt, Belgium
Objectives: To quantify which factors affect the quality of life valuations (QoL) of 
patients after stroke. MethOds: 569 ischemic stroke patients were recruited into 
a retrospective, observational study in 10 teaching and regional hospitals across 
Belgium. Patients were stratified according to their modified Rankin Score (mRS) 
ranging from 0 (full health) to 5 (severely dependent). QoL as measured by the EQ5D 
and the VAS were collected for their health status before and after the index stroke. 
Utility decrements were calculated and using a general linear model the relationship 
between a set of variables and quality of life evaluation and its decrement associ-
ated with the stroke experience was investigated. Different distributions and link 
functions were tested against each other using the AICC and BIC criterion. Results: 
Stroke had a significant effect on patient’s QoL: a positive relationship with the 
degree of disability was found: EQ5D decrements were 0.08, 0.17, 0.25, 0.40, 0.64 and 
0.75 for mRS categories 0 to 5; and equivalent decrements on the VAS scale were 
7, 11, 20, 27, 33 and 39. The EQ5D and VAS decrements were significantly related 
to each other (r= 0.49, p< 0.001) and the decrements were also correlated with their 
baseline values (r= -0.74 for EQ5D baseline measurement and its decrement; r= -0.55 
for VAS baseline value and decrement, p< 0.001). The decrements were of higher 
magnitude when measured by the EQ5D compared to the VAS. Furthermore the 
utility decrements were significantly associated with being female, being diabetic, 
having atrial fibrillation, being in a wheelchair, experiencing a change in one’s living 
situation and the number of days spent in an inpatient care facility during the first 
3 months after stroke. cOnclusiOns: Stroke results in a significant decrease in 
patient’s QoL, the magnitude of which is related to patient characteristics, disease 
severity measures, clinical risk factors and living circumstances.
Ql4
DIffereNces betweeN hypothetIcal aND experIeNce-baseD value sets 
for eQ-5D: ImplIcatIoNs for DecIsIoN makers
Aronsson M., Husberg M., Kalkan A., Eckard N., Alwin J.
Linköping University, Linköping, Sweden
Objectives: The aim of the study was to analyse the differences between hypo-
thetical and experience-based EQ-5D value sets. Furthermore, the aim was to evalu-
ate the health economic implications of such differences for policy decisions in 
health care. MethOds: We studied the differences in hypothetical and experience-
based value sets using three different methods: numerical comparison, empirical 
Replicating a published regression predicting EQ-5D based on Health Assessment 
Questionnaire (HAQ) and Psoriasis Area and Severity Index (PASI) scores, however, 
led to subtle yet statistically significant differences in coefficients (Gray EQ-5D = 
0.782 -0.196xHAQ -0.00227xPASI vs. Rowen EQ-5D = 0.816 -0.220xHAQ –0.0231xPASI). 
In this analysis the Rowen algorithm was more sensitive to changes in disease sta-
tus, which is potentially important in a disease area with multiple available thera-
pies. cOnclusiOns: The choice of mapping algorithm has the potential to affect 
the results of analyses performed. Although mean values obtained from different 
mapping algorithms may be similar, regression coefficients were shown to differ by 
mapping algorithm. Analyses using all available mappings should be presented to 
avoid accusations of ‘cherry picking’ the most favourable estimate. When suggesting 
the most appropriate analysis, clear justification should be provided.
pr3
INvestIgatINg the Impact of perspectIve oN weIghtINg Qalys:  
a DIscrete choIce experImeNt
Butt T.1, Longworth L.2, Rubin G.1, Orr S.1
1University College London, London, UK, 2Brunel University, Uxbridge, UK
Objectives: Discrete choice experiments (DCEs) are increasingly used to elicit 
preferences for weighting QALYs by other characteristics. Recent studies for weight-
ing QALYs have asked respondents to take the role of decision maker and prioritize 
treatment options for groups of patients (‘someone else’). The procedure normally 
used to obtain preferences for health states is for respondents to consider oneself in 
that state from behind a veil of ignorance. The aim of this study was to elicit public 
preferences for weighting QALYs by other characteristics, and to test if the decision-
maker perspective or naming the condition is equivalent to choosing for oneself 
from behind a veil of ignorance. MethOds: A DCE was developed with attributes 
for health gain, severity, unmet need and process of care. Four questionnaires were 
designed to reflect three different perspectives and one alternative framing: a) ‘one-
self’ b) ‘someone like oneself’ c) ‘someone else’ d) ‘someone else’ with a disease label 
(age-related macular degeneration). 800 members of the public were recruited via an 
online survey panel, with 200 completing each of the four questionnaires. Results 
were analysed using a conditional logit model and utility weights derived using 
Hicksian compensating variation. Results: Attributes of health gain, severity and 
process of care were significant for all perspectives (p< 0.05). Respondents preferred 
treatments that offered greater health gain, for a higher severity (lower starting 
level of health), and more convenient process. Unmet need was significant only in 
the ‘oneself’ perspective with respondents preferring treatments that addressed 
an unmet need. cOnclusiOns: Members of the public are willing to trade health 
gain for other characteristics. These include severity, process of care, and in some 
cases unmet need. There is evidence that preferences for weighting QALYs vary by 
perspective. The study may help inform criteria for decision-making when prioritiz-
ing health care resources.
pr4
valuINg eQ-5D-5l: Does the orDerINg of the health DImeNsIoNs 
Impact oN health state valuatIoNs?
Mulhern B.1, Shah K.2
1University of Sheffield, Sheffield, UK, 2Office of Health Economics, London, UK
Objectives: Health states defined by multi-attribute instruments such as the 
EQ-5D-5L can be valued using Time Trade Off (TTO) or Discrete Choice Experiment 
(DCE) methods. A key feature of the tasks is the order in which the health state 
dimensions are presented to respondents. This is because respondents may use 
a variety of heuristics to answer the questions (for example focusing on the first 
dimension presented), and therefore the order of the dimensions may impact on 
the importance assigned to particular health state descriptions. The objective of 
this study is to assess the impact of different EQ-5D-5L dimension orderings on 
health state valuations. MethOds: Preferences for EQ-5D-5L health states were 
elicited from a broadly representative sample of members of the UK general public. 
Respondents were allocated to one of three EQ-5D-5L dimension orderings, and 
completed 10 TTO and 9 DCE tasks via a computer assisted personal interview 
carried out in their home. Differences in mean values and the relative importance 
of the coefficients across the arms were compared using difference testing and 
regression analyses. Results: Descriptive analysis suggests that there are minimal 
differences between the mean TTO health state values across the different dimen-
sion orderings. Regression analysis suggests that the magnitude of the dimension 
coefficients differs across the different dimension orders (for both TTO and DCE), 
but there is no clear pattern. cOnclusiOns: There is some evidence that the 
order in which the dimensions are presented impacts on the coefficients, which may 
impact on the health state values provided. The order of dimensions is an important 
consideration in the design of health state valuation studies.
QualIty of lIfe aND utIlIty stuDIes
Ql1
elIcItatIoN of health state utIlItIes assocIateD wIth varyINg 
severItIes of flare IN systemIc lupus erythematosus
Hartz S.1, Liu-Leage S.2, Paget M.A.2, Pollard C.3, Cook J.3, Enstone A.3
1Lilly Research Centre, Surrey, UK, 2Lilly France, Cedex, France, 3Adelphi Values, Bollington, UK
Objectives: Systemic Lupus Erythematosus (SLE) is characterised by fluctuat-
ing periods of minimal disease activity and ‘flare’. Flare is an important outcome 
variable impacting the economic and humanistic burden of SLE. The objective of 
this study was to obtain population-based utility values for varying severities of 
flare to measure the impact on health-related quality of life (HRQoL). MethOds: 
Six health states (HS) for varying severities of flare were developed based on lit-
erature, patient blogs, and interviews with patients (n= 12), rheumatologists (n= 7) 
and nurses (n= 2). HS were verified by independent clinical experts (n= 6) and pilot 
interviews (n= 10, UK). HS were evaluated using the time-trade-off (TTO) method 
